Metraipolis › archive › dc_ff50507b48e9
Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA Therapy — Europe PMC PMID:41041047
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41041047
- DOI
- 10.7150/thno.113614
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T06:27:07.872Z
- SHA-256 of the archived text
9c5bf0e2297b86f36420609d2095117c998ef27405fc0d940775b99a19e82fe4- Stable URL of this page
https://metraipolis.com/documento/dc_ff50507b48e9
How to cite
Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA Therapy — Europe PMC PMID:41041047 — Europe PMC (en), https://europepmc.org/article/MED/41041047 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ff50507b48e9 (Metraipolis archive dc_ff50507b48e9, sha256 9c5bf0e2297b86f36420609d2095117c998ef27405fc0d940775b99a19e82fe4)
BibTeX
@misc{dcff50507b48e9,
title = {Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA Therapy — Europe PMC PMID:41041047},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41041047},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ff50507b48e9; sha256 9c5bf0e2297b86f36420609d2095117c998ef27405fc0d940775b99a19e82fe4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41041047. Agents can read the archived copy with the MCP tool read_document.